Cost-benefit analysis of funding a smoking cessation program before surgery

For patients undergoing surgery, smoking is linked with a higher risk of experiencing complications following their procedure, and quitting smoking before surgery may help reduce this risk. A new BJS (formerly British Journal of Surgery) study examined whether a smoking cessation intervention before surgery is economically worthwhile when funded by the National Health System (NHS)…

Details

Cancer survivors’ experiences with financial toxicity

Many cancer survivors with high medical copayments experience financial toxicity, an economic side effect of cancer treatment. A recent analysis of published studies found that few cancer survivors received financial information support from healthcare facilities during their initial treatment, even though cancer-related financial toxicity has multiple impacts on survivors’ health and quality of life. The…

Details

Work-related PTSD in nurses

A recent analysis of published studies examined the prevalence of post-traumatic stress disorder (PTSD) among nurses and identified factors associated with work-related PTSD among nurses. The findings are published in the Journal of Clinical Nursing. For the analysis, investigators identified 24 relevant studies. The researchers found that PTSD is a world-wide issue affecting nurses and…

Details

Study reveals impact of ‘soft opt-out’ system for organ donation

Research published in Anaesthesia suggests that a “soft opt-out” system may increase consent rates for organ donation after death, which could boost the number of organs available for transplantation. The legal frameworks for consent for deceased organ donation fall into two major categories: opt-in, where expressed consent is required from the patient or their relatives,…

Details

Interleukin-12 electroporation may sensitize ‘cold’ melanomas to immunotherapies

Bottom Line: Combining intratumoral electroporation of interleukin-12 (IL-12) DNA (tavokinogene telseplasmid, or TAVO) with the immune checkpoint inhibitor pembrolizumab (Keytruda) led to clinical responses in patients with immunologically quiescent advanced melanoma, according to results from a phase II trial. Journal in Which the Study was Published: Clinical Cancer Research, a journal of the American Association…

Details